SOPH

SOPHiA GENETICS SA

3.74 USD

Last updated Dec 2, 18:39 UTC

Yesterday HIGH

$4.2

Yesterday LOW

$3.96

52w HIGH

$5.77

52w LOW

$1.85

EPS

-0.21

PE

-17.81

Next Earnings

Mar 5, 2024

Overview News Government Trades

SOPHiA GENETICS SA stock is down -5.56% since 30 days ago. The next earnings date is Mar 5, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 2 December’s closed higher than November.

SOPHiA GENETICS SA operates as a healthcare technology company. The company offers a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Company was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

-

Website

sophiagenetics.com

Benzinga Insights

Mon Mar 20, 2023

12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights

Tue Mar 14, 2023

12 Health Care Stocks Moving In Tuesday's After-Market Session
Bill Haddad

Tue Mar 14, 2023

SOPHiA GENETICS DDM Platform To Be Integrated With Agilent's SureSelect Cancer Comprehensive Genomic Profiling Assay Kit
Benzinga Newsdesk

Wed Mar 8, 2023

Morgan Stanley Maintains Overweight on Sophia Genetics, Lowers Price Target to $11

Morgan Stanley analyst Tejas Savant maintains Sophia Genetics (NASDAQ:SOPH) with a Overweight and lowers the price target from $12 to $11.
Benzinga Newsdesk

Tue Mar 7, 2023

Sophia Genetics Expects FY23 Revenue Growth To Be At Or Above 30%

Full year constant currency revenue growth excluding COVID-19-related revenue to be between 30% and 35%; and 2023 operating losses to be below 2022 levels.
Benzinga Newsdesk

Tue Mar 7, 2023

Sophia Genetics Q4 Adjusted EPS $(0.17) Beats $(0.36) Estimate, Sales $13.38M Beat $12.91M Estimate

Sophia Genetics (NASDAQ:SOPH) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.36) by 52.78 percent. This is a 39.29 percent increase over losses of $(0.28) per share from
Benzinga Insights

Tue Mar 7, 2023

Earnings Scheduled For March 7, 2023

Companies Reporting Before The Bell • Cohen & Co (AMEX:COHN) is likely to report earnings for its fourth quarter. • Xtant Medical Holdings (AMEX:XTNT) is expected to report earnings for its fourth quarter.
Benzinga Newsdesk

Mon Mar 6, 2023

University Of Arkansas For Medical Sciences Will Use SOPHiA GENETICS' SOPHiA DDM Platform For Research On Hematologic Malignancies
Happy Mohamed

Wed Mar 1, 2023

SOPHiA GENETICS And QIAGEN Forge Partnership To Combine Strengths In Next-generation Sequencing

SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company in the healthcare space, today announced a new partnership with QIAGEN N.V. (NYSE:QGEN) that will pair QIAseq reagent technology with the SOPHiA
Happy Mohamed

Tue Feb 28, 2023

Synergy Laboratories Taps SOPHiA GENETICS TechnologyFor New Cancer Profiling Solution; No Financial Terms Disclosed

The New Solution uses SOPHiA DDM™ and aims to Benefit Cancer Research, Clinical Studies and Patient Care SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company in the healthcare space, today announced that